JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gorelick, R J
Right arrow Articles by Rein, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gorelick, R J
Right arrow Articles by Rein, A

 Previous Article  |  Next Article 

J Virol. 1990 July; 64(7): 3207-3211

Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA.

R J Gorelick, S M Nigida Jr, J W Bess Jr, L O Arthur, L E Henderson and A Rein

Laboratory of Molecular Virology and Carcinogenesis, National Cancer Institute-Frederick Cancer Research Facility, Maryland 21701-1013.

ABSTRACT

All retroviruses contain, in the nucleocapsid domain of the Gag protein, one or two copies of the sequence Cys-X2-Cys-X4-His-X4-Cys. We have generated a series of mutants in the two copies of this motif present in human immunodeficiency virus type 1. These mutants encoded virus particles that were apparently composed of the normal complement of viral proteins but contained only 2 to 20% of the normal level of genomic RNA. No infectivity could be detected in the mutant particles, while 10(5) infectious U were present in an equivalent amount of wild-type particles. Thus, the mutants have another defect in addition to the inefficiency with which they encapsidate genomic RNA. Our results show that both copies of the motif are required for normal RNA packaging and for infectivity. Mutants of this type may have important applications, including nonhazardous materials for research, immunogens in vaccine and immunotherapy studies, and diagnostic reagents.


J Virol. 1990 July; 64(7): 3207-3211




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1990 by the American Society for Microbiology. All rights reserved.